CapsoVision, Inc.

CapsoVision, Inc.

NNASDAQ:CV
6.47
USD
+0.44
(+7.30%)
-0.63EPS
379.24MMarket Cap
Apr 01Next Earn
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.25
0.25
0.29
0.29
Basic EPS, GAAP
-0.29
-0.43
-0.54
-0.63
Free Cash Flow per Basic Share
-0.3
-0.44
-0.49
-0.59
Dividend per Share
- -
- -
- -
- -
Book Value per Share
-3.77
-4.51
0.28
0.26
Tangible Book Value per Share
-3.77
-4.51
0.28
0.26
Basic Weighted Avg Shares
39
46
47
48
Sales/Revenue/Turnover
10
12
14
14
Operating Margin (%)
-116.34
-169.42
-188.25
-217.09
Depreciation Expense
- -
1
1
1
Net Income, GAAP
-11
-20
-25
-30
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
-115.91
-169.26
-186.77
-214.74
Working Capital
18
13
12
12
LT Debt
1
1
- -
- -
Total Equity
-110
-130
13
13
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
47
50
50
Market Capitalization
501
363
379

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
17
25
17
Cash, Cash Equivalents & STI
10
18
9
Accounts Receivable, Net
2
2
2
Inventories
3
3
5
Total Current Liabilities
4
5
5
Payables & Accruals
3
4
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-110.24%
Free Cash Flow
- -
- -
13.39%
Net Income, GAAP
- -
- -
27.22%
Sales/Revenue/Turnover
- -
- -
15.29%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
3
3
3
12
2025
3
3
4
4
14
2026
3
4
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.1
-0.13
-0.14
-0.1
-0.43
2025
-0.12
-0.1
-0.17
-0.16
-0.54
2026
-0.15
-0.15
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Kang-Huai Wang
Full Time Employees
99
Sector
Health technology
Industry
Medical specialties
Address
18805 Cox Avenue Saratoga CA United States 95070
IPO Date
Jul 2, 2025
Business
CapsoVision, Inc. (NASDAQ: CV) develops and commercializes advanced imaging and artificial intelligence-enabled capsule endoscopy solutions for the detection and diagnosis of gastrointestinal diseases. The company offers CapsoCam Plus, a wire-free, single-use capsule endoscope providing 360-degree panoramic visualization of the small bowel mucosa in adults and children aged two years and above; CapsoCam Colon for non-invasive colon imaging, polyp detection, and measurement; and CapsoColon 3D in development for large intestine applications. Complementary products and services include CapsoCloud, a cloud-based software-as-a-service platform for remote video access, download, and AI-assisted analysis; CapsoAccess, a capsule data retrieval system; CapsoView software for direct video review; CapsoRetrieve retrieval kit using magnetic technology; and capsule video reading services. CapsoVision serves gastroenterologists, medical practices, clinics, and hospitals, selling directly in the United States and through exclusive distributors internationally, with key markets in France, Germany, and Canada. The company operates globally from its headquarters in Saratoga, California, where it was incorporated in 2005, and established a direct sales team in Germany in 2023 to expand its European presence. Recent developments include the completion of an initial public offering in July 2025, raising net proceeds of $23.4 million; submission of an FDA Breakthrough Device Designation application in November 2025 for a capsule targeting early-stage pancreatic cancer detection; entry into a development agreement with Canon Inc. in 2025 for higher-resolution CMOS image sensors; appointment of David Garcia as Senior Vice President of Finance in November 2025; advancement of AI-assisted reading updates for CapsoCam Plus with planned FDA submission by end-2025; and commencement of clinical enrollment for a next-generation colon capsule.

Company News

  • CapsoVision, Inc. (CV) Q3 2026 Earnings Call Transcript

  • What CapsoVision (CV) Said on Its Q3 Earnings Call

  • CapsoVision Reports Third Quarter 2026 Financial Results

  • CapsoVision (NASDAQ:CV) Share Price Crosses Above 200 Day Moving Average – What’s Next?

  • CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026

  • CapsoVision Maps AI Capsule Push Into Colon, Pancreatic Cancer Screening

  • SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

  • CapsoVision to Present at the 20th Annual LD Micro Main Event

  • New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

  • Head to Head Survey: CapsoVision (NASDAQ:CV) vs. Brainsway (NASDAQ:BWAY)

  • CapsoVision (NASDAQ:CV) and NeuroPace (NASDAQ:NPCE) Critical Contrast

  • AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress

  • CapsoVision gets FDA clearance for AI Highlights

  • CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®

  • CapsoVision (NASDAQ:CV) Major Shareholder Eliyahou Et Al Harari Purchases 1,757,469 Shares

  • AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis

  • Critical Contrast: Zimmer Biomet (NYSE:ZBH) versus CapsoVision (NASDAQ:CV)

  • BlackRock Inc. Acquires New Shares in CapsoVision, Inc. $CV

  • CapsoVision to Participate in Upcoming Investor Conferences

  • Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings